Cellular Immunotherapy Program News Today

A flurry of new studies suggest scientists are finally figuring out how to harness the immune system to attack a ruthless form of brain cancer. While preliminary, the results offer

Two early trials published Wednesday showed promise in treating one of the deadliest types of cancer, glioblastoma, using CAR-T therapy.

Ciara Freeman, MD, PhD, discusses findings from a longitudinal single-cell analysis that was conducted to pinpoint factors linked to either a positive response or therapeutic failure with FDA-approved, BCMA-directed CAR T-cell therapy in patients with hematologic malignancies.

Experimental safety switch reduces severity of CAR-T immunotherapy-related side effects UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur. This advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia. It demonstr...

 E-Mail IMAGE: Matthew Foster, MD, and his UNC Lineberger colleagues have used an experimental safety switch incorporated as part of a chimeric antigen receptor-modified T cell therapy (CAR-T) for an aggressive form... view more  Credit: UNC Lineberger Comprehensive Cancer Center CHAPEL HILL, North Carolina--UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) the...